title: Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.
abstract: In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) that is overexpressed in a wide range of acute myeloid leukemia (AML) cases, but not in normal hematopoietic precursors. This finding suggests a potentially unique therapeutic targeting opportunity for this difficult-to-treat disease.
authors.affiliation: Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: Karilyn
authors.initials: K
authors.lastname: Larkin
authors.affiliation: Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, B302 Starling-Loving Hall, 320 West 10(th) Avenue, Columbus, OH 43210, USA. Electronic address: john.byrd@osumc.edu.
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
mesh_terms: D000818:Animals; D049071:Endopeptidase Clp / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology*; D008297:Male
chemical_list: D004791:Enzyme Inhibitors; D049071:Endopeptidase Clp